 | | Vol. 13.14 – 22 April, 2022 |
| |
|
|
| Scientists utilized medical record data, patient samples, and in vivo models to evaluate the impact of inflammation, as seen in autoimmune diseases, on prostate tissue.
[Nature Communications] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators described a new role for SPOP as a negative regulator of autophagy and NFE2L2 pathway activation. SPOP bound and induced the non-degradative ubiquitination of SQSTM1 at Lys420.
[Autophagy] |
|
|
|
| Scientists showed that PLK1 could interact with Smad4 and promote the ubiquitination and degradation of Smad4 in prostate cancer cells. PLK1 and PELO could bind to different domains of Smad4 and formed a protein complex.
[Oncogene] |
|
|
|
| Bioinformatics and immunohistochemical analyses demonstrated that RNF8 was high expressed in prostate cancer and CRPC samples and the expression of RNF8 was positively correlated with the Gleason score.
[Cell Death & Disease] |
|
|
|
| Scientists found 3JC48-3 decreased prostate cancer cells’ growth and viability in a dose-dependent fashion in vitro.
[Cancer Gene Therapy] |
|
|
|
| Researchers suggested that fat mass and obesity-associated protein (FTO) suppressed prostate cancer proliferation and metastasis through reducing the degradation of CLIC4 mRNA in an m6A dependent manner.
[Cell Death Discovery] |
|
|
|
| Scientists performed chromatin immunoprecipitation sequencing in patient-derived castration-resistant androgen receptor-negative prostate cancer cells to identify genes that were regulated by OCT1.
[Scientific Reports] |
|
|
|
| Investigators showed that interferon-γ treatment induced expression of major histocompatibility class-I genes and PD-L1 in prostate cancer cells in vitro.
[Scientific Reports] |
|
|
|
| Biochanin A inhibited 3βHSD1 and suppressed prostate cancer development alone or together with abiraterone and enzalutamide.
[Cell Reports Medicine] |
|
|
|
| Scientists identified prognostic biomarkers and described the heterogeneity of prostate cancer and the associated microenvironment by simultaneously quantifying 36 proteins using single-cell mass cytometry analysis of over 1.6 million cells from 58 men with localized prostate cancer.
[Cell Reports Medicine] |
|
|
|
|
| Understanding precision medicine, personalized cancer risk management and syndrome-related cancer risk management is important in order to develop collaborative strategies with genetic counselling for optimal care of patients and their families
[Nature Reviews Urology] |
|
|
|
| Scientists assess and compare the clinical efficacy and safety of prostatic urethral lift and prostatic artery 2mbolization for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.
[BJU International] |
|
|
|
| The authors assess the documented impact of prostate-specific membrane antigen (PSMA)-PET on patient management and outcomes, including prostate-specific antigen response, and intermediate and long-term outcome measures.
[Prostate Cancer and Prostatic Diseases] |
|
|
|
|
| L-Nutra Inc. announced data from a first-of-its-kind study evaluating the impact of its Fasting Mimicking Technology on metabolic risk factors in patients with prostate cancer.
[L-Nutra, Inc. (Businesswire, Inc.)] |
|
|
|
|
| June 20 – 23, 2022
Sevilla, Spain |
|
|
|
|
|
| | City of Hope – Duarte, California, United States |
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | Washington State University – Spokane, Washington, United States |
|
|
|
| | Helmholtz Munich – Neuherberg, Germany |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
